Universe Pharmaceuticals Inc filed a prospectus with the US Securities and Exchange Commission (SEC) for a mixed shelf offering valued at $200 million. The filing outlines the potential issuance of various securities, including ordinary shares and warrants.

The registration statement includes provisions for the sale of securities by the company and by selling shareholders. Specifically, the prospectus covers 4.377 million Class A ordinary shares held by selling shareholders, indicating a secondary component to the broader capital raise structure.

Offering Structure

The mixed shelf format allows the company flexibility in timing and type of securities issued. The key components disclosed in the filing include:

• Total aggregate offering value: $200 million
• Selling shareholder shares: 4.377 million Class A ordinary shares
• Regulatory body: US Securities and Exchange Commission

Regulatory Filing Details

The document was submitted via the SEC's EDGAR system. The filing references the specific accession number associated with the Form F-3 registration statement. This type of filing is typical for foreign private issuers seeking to register multiple types of securities for future sale in the US markets.

No specific use of proceeds or pricing details were included in this initial prospectus draft, as is standard for shelf registrations which allow for subsequent takedowns.

Universe Pharmaceuticals Inc. (NASDAQ: UPC) shares climbed 38.64% to $5.92 in after-hours trading on Tuesday. The surge followed the disclosure of significant ownership stakes by eight entities, largely linked to shares issued for a recent patent acquisition.

The stock closed the regular session at $4.27, down 6.77%, according to Benzinga Pro data. The after-hours move reflects market reaction to new regulatory filings rather than operational results.

Eight Investors Disclose Ownership Stakes

Eight Schedule 13G filings were submitted to the Securities and Exchange Commission on Tuesday. A Schedule 13G is a short-form beneficial ownership report filed when an investor acquires more than 5% of a public company’s equity securities without the intent to change or influence control.

The filings revealed that British Virgin Islands-registered entities, each wholly owned by a single individual, now hold the bulk of Universe Pharmaceuticals’ Class A shares.

Origin Force Intelligence Limited, controlled by Piao Ye, holds the largest stake at 18.30%. This position is roughly twice the size of any other single filer. Seven other entities hold stakes ranging from 9.29% to 9.98%.

Shareholders To Vote On Reverse Split

In a separate filing on Tuesday, Universe Pharmaceuticals announced its annual general meeting scheduled for Sept. 30. Shareholders of record as of Aug. 31 will vote on re-electing five directors and on a proposed 1-for-10 share consolidation.

Shares Trace Back To Patent Acquisition

The disclosed ownership stakes correspond to shares issued as consideration for Universe Pharmaceuticals’ acquisition of Best Praise International Limited, which closed Jun. 30. The deal, outlined in a share purchase agreement dated Jun. 17, provided the company with five China-based patents covering pharmaceutical compounds and drug-delivery technologies.

These patents target age-related diseases, neurodegenerative conditions, cognitive disorders, and cardiovascular applications. Universe Pharmaceuticals issued 4.37 million Class A ordinary shares as consideration for the deal. These were restricted securities issued under an exemption from standard registration requirements.

Following the issuance, the company has 5.01 million Class A ordinary shares and 16,077 Class B ordinary shares outstanding.

What the Numbers Show

The issuance of 4.37 million shares for the patent acquisition represents approximately 87% of the company’s total outstanding Class A ordinary shares (5.01 million). This indicates that the recent capital structure is heavily concentrated among the acquirers of these specific intellectual property rights, with the eight disclosed filers holding the vast majority of the equity.

Trading Metrics, Technical Analysis

Universe Pharmaceuticals has a market capitalization of $21.45 million. The stock has a 52-week high of $17.96 and a 52-week low of $2. The Relative Strength Index (RSI) stands at 41.78.

The stock has risen 21.65% over the past 12 months. UPC is currently positioned near the lower end of its 52-week range, at about 14.2% of the annual band.